 Connection
Paul Buehler to Human Umbilical Vein Endothelial Cells
This is a "connection" page, showing publications Paul Buehler has written about Human Umbilical Vein Endothelial Cells.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.129 |
|
|
|
-
Vallelian F, Schaer CA, Deuel JW, Ingoglia G, Humar R, Buehler PW, Schaer DJ. Revisiting the putative role of heme as a trigger of inflammation. Pharmacol Res Perspect. 2018 04; 6(2):e00392.
Score: 0.036
-
Schaer CA, Owczarek C, Deuel JW, Schauer S, Baek JH, Yalamanoglu A, Hardy MP, Scotney PD, Schmidt PM, Pelzing M, Soupourmas P, Buehler PW, Schaer DJ. Phenotype-specific recombinant haptoglobin polymers co-expressed with C1r-like protein as optimized hemoglobin-binding therapeutics. BMC Biotechnol. 2018 03 15; 18(1):15.
Score: 0.036
-
Deuel JW, Vallelian F, Schaer CA, Puglia M, Buehler PW, Schaer DJ. Different target specificities of haptoglobin and hemopexin define a sequential protection system against vascular hemoglobin toxicity. Free Radic Biol Med. 2015 Dec; 89:931-43.
Score: 0.031
-
Lipiski M, Deuel JW, Baek JH, Engelsberger WR, Buehler PW, Schaer DJ. Human Hp1-1 and Hp2-2 phenotype-specific haptoglobin therapeutics are both effective in vitro and in guinea pigs to attenuate hemoglobin toxicity. Antioxid Redox Signal. 2013 Nov 10; 19(14):1619-33.
Score: 0.026
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|